Replies to post #658989 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

Happy holidays!

I think my post was not clear enough. All new trials after Jan. 31, 2023 have to be registered. I don't think an inquiry call to the school would be helpful as I am sure this trial is highly confidential.

https://www.clinicaltrialsregister.eu/

My conjecture is that the trial is DCVax-L + Poly-ICLC + Keytruda since I strongly believe after 2016 DCVax-L by default always means DCVax-L + Poly-ICLC.

If the combination of the three can trigger antitumor response so intense that rGBM patients had to go through surgery to remove the inflammation tissue, I have no doubt the results on colorectal cancer would be amazing too. I assume in colorectal cancer case the patients don't need surgery to deal with inflammation tissue since there is always room to accommodate the expansion outside skull.

I have medical background. The above is my speculation.

[barnstormer]

Gary, if I recall correctly the word was the trial had been suspended/put on hold as there wasn't funding available to pursue it and the DCvax-L Glioblastoma study at the same time. The company has operated on a financial shoestring for years and they probably couldn't afford a second one. FWIW, and I suspect you have this information already, the trial’s identifier on ClinicalTrials.gov is NCT02982941, but the record has not been updated since January 2017. The original objective was to test the safety and efficacy of DCVax-L and Pembrolizumab in 30 patients with microsatellite stable colorectal cancer that has spread to the liver. The January 2017 update increased the estimated enrollment from 30 to 40 participants. The estimated primary completion date was changed from December 2018 to December 2019, and the estimated study completion date was changed from December 2019 to December 2020. The eligibility criteria were revised to include patients with KRAS wild-type tumors and exclude patients with KRAS mutant tumors, and the study design was updated to include an interim analysis after 20 patients had completed 12 weeks of treatment.